Tuesday, 20 Mar 2018

You are here

Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture


Among older patients using medium to high doses of the anti-inflammatory steroid prednisolone, treatment with the osteoporosis drug alendronate was associated with a significantly lower risk of hip fracture, according to a study published by JAMA.

Although glucocorticoid therapy is widely used to treat inflammatory conditions, it can lead to rapid bone loss and is associated with an increased rate of fracture. Evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids. Using a national database, Mattias Lorentzon, M.D., Ph.D., of the University of Gothenburg, Sweden, and colleagues identified 1,802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment, and 1,802 patients taking prednisolone without alendronate use.

The average age of the patients was 80 years; 70 percent were women. After a median follow-up of 1.3 years, there were 27 hip fractures in the alendronate group and 73 in the no-alendronate group. Analyses indicated that alendronate treatment for a median duration of 2.9 years was associated with lower risk of hip fracture than no alendronate treatment. Greater duration of treatment was associated with a lower risk of hip fracture.

“Although the findings are limited by the observational study design and the small number of events, these results support the use of alendronate in this patient group,” the authors write.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Limited Utility of Arthroscopic Meniscal Surgery

JAMA Surgery reports that arthroscopic partial meniscectomy (APM) is still one of the most common surgeries performed, despite evidence from large trials (eg, FIDELITY study) showing that APM is no more effective than exercise and physical therapy, especially in adults over age 65 years.

Hip Replacement Augments Longevity

Data from Swedish hip replacement registry finds that total hip arthroplasty not only improves quality of life, it is also associated with increased life expectancy that lasts for 10 years after surgery, especially in primary osteoarthritis patients.

HERO Trial - Hydroxychloroquine Fails in Hand Osteoarthritis

UK researchers have treated 248 patients with moderate to severe hand pain and radiographic osteoarthritis (OA) and demonstrated no benefit after 12 months of hydroxychloroquine (HCQ), according to a recent article in Annals of Internal Medicine.

Teriparatide Superior to Risedronate in the VERO Trial

Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.

This trial is one of the first to compare osteoporosis drugs with incident fractures as the primary outcome.

Two Types of Osteoarthritis Based on Cartilage Studies

A report from Annals of Rheumatic Diseases suggests that osteoarthritis (OA) may be two distinct diseases based on genetic studies of articular cartilage. (Citation source: https://buff.ly/2mNtUsL).

RNA sequencing of knee cartilage from 44 OA patients undergoing total knee replacement was compared to 6 additional patients with OA and 10 control patients with non-OA.